NCT03832920 (ANIBPV) is a clinical trial of Analgesia Nociception Index in Breast Cancer, sponsored by Institut de Cancérologie de Lorraine.

Who is sponsoring NCT03832920?

NCT03832920 is sponsored by Institut de Cancérologie de Lorraine.

What drugs are being tested in NCT03832920?

Interventions in NCT03832920: Analgesia Nociception Index.

What condition does NCT03832920 study?

NCT03832920 studies Breast Cancer.

Is NCT03832920 still recruiting?

NCT03832920 is currently completed. Last updated 2 January 2026.

Last reviewed 2026-01-02 · How we verify

NCT03832920: ANIBPV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analgesia Nociception Index (ANI) After Unilateral Radical Mastectomy as an Evaluation of Paravertebral Block Failure

Completed Last updated 2 January 2026

What this trial tests

trial testing Analgesia Nociception Index in Breast Cancer in 100 participants. Completed in 1 March 2023.

Timeline

2 May 2019

Primary endpoint
26 June 2020

1 March 2023

Quick facts

Lead sponsor	Institut de Cancérologie de Lorraine
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	2 May 2019
Primary completion	26 June 2020
Estimated completion	1 March 2023
Sites	1 location across France

Drugs / interventions tested

Analgesia Nociception Index

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institut de Cancérologie de Lorraine — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Paravertebral Block (PVB) combined with general anesthesia (GA) is a conventional pain treatment for breast surgery but sometimes failures can occurs. The efficacy of this block has to be evaluated. Also, for the intra-operative analgesic evaluation of this block, it is necessary to measure intra-operative analgesia index. A monitor of nociception for patients under GA, the PhysiodolorisTM device, offers an index for measuring nociceptive inputs during surgery in anesthetized patients : the ANI index (based on the single R-R interval analysis). The purpose of this observational and prospective study is to assess the variations of this ANI index during breast surgery with or without axillary node dissection with a PVB. This will allow us to quantify the analgesic effect of a PVB during GA for unilateral radical breast surgery with or without axillary node dissection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Analgesia nociception index as a tool to assess the effectiveness of paravertebral block in total mastectomy: a prospective cohort study.
Raft J, Lamotte AS, Schohn CH, Fritz C, et al · · 2026 · PMID 41207559 · DOI 10.1016/j.bjane.2025.844699

Verify or expand the search:

Other trials of Analgesia Nociception Index

Trials testing the same drug.

NCT04154410 — Prediction of Pre-operative Anxiety by Heart Variability and Pupillometry · completed
NCT03498820 — Analgesia-Nociception Index Guided Intraoperative Remifentanil Administration Versus Standard Practice:Evaluation of Per · NA · completed
NCT02364856 — Pain Assessment in Children With Cerebral Palsy Through Parasympathetic Tone Analysis. · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institut de Cancérologie de Lorraine trials

Trials by the same sponsor.

NCT07326800 — Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cance · NA · recruiting
NCT07089485 — Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees · NA · not yet recruiting
NCT07165756 — "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot S · recruiting
NCT06884332 — Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality · NA · recruiting
NCT06903104 — Acceptability and Feasibility of a Stress Prevention Program Based on Meditation and Acceptance and Commitment Therapy f · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03832920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut de Cancérologie de Lorraine
Last refreshed: 2 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03832920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing